openPR Logo
Press release

Phenylketonuria Treatment Market Challenges with Top Players BioMarin Pharmaceutical,Dimension Therapeutics, American Gene, Synthetic Biologics

07-06-2019 08:23 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Phenylketonuria Treatment

Phenylketonuria Treatment

Phenylketonuria (PKU) is a rare genetic disorder caused due to increased level of phenylalanine in the blood. The excess amount of phenylalanine can cause intellectual disability and other serious health problems. The most severe condition of this disorder is termed as classic PKU and symptoms related to it are seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions such as eczema, and musty odor of their breath, skin, or urine. PKU can be managed by maintaining phenylalanine free diet. KUVAN (sapropterin dihydrochloride) is a U.S. Food and Drug Administration approved drug which is majorly used in the treatment of Phenylketonuria.

Phenylketonuria Treatment Market Drivers

Frequent research for development of novel drugs for the treatment of phenylketonuria is expected to drive growth of global phenylketonuria treatment market in the near future. For instance, in 2017, BioMarin Pharmaceutical Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its new Pegvaliase, indicated for the treatment of patients with Phenylketonuria (PKU). In 2018, European Medicines Agency (EMA) accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of adults with phenylketonuria (PKU) who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l). In 2017, Synlogic, Inc. received Orphan Drug Designation for its SYNB1618 from U.S. Food and Drug Administration. SYNB1618, an orally administered synthetic biotic medicine indicated for the treatment of PKU. Furthermore, increasing acquisitions and collaborations between key players is also expected to create a lucrative environment for growth of global phenylketonuria treatment market. For instance, in 2015, BioMarin Pharmaceutical Inc. acquired all global rights of Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono (Merck). Kuvan is an oral therapy indicated for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU). Pegvaliase (PEGylated recombinant phenylalanine ammonia lyase) is an investigational enzyme substitution therapy for the treatment of phenylketonuria (PKU). In 2016, Dimension Therapeutics, Inc. entered into a gene therapy research collaboration with the University of Pennsylvania for research and development of novel treatment for phenylketonuria.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1648

Phenylketonuria Treatment Market Regional Analysis

North America is expected to hold a dominant position in global phenylketonuria treatment market, owing to initiatives taken by governments for the diagnosis and treatment of phenylketonuria in the region. For instance, in 2017, The National PKU Alliance and Baby Genes launched a program to allow easy access to genetic testing for people with phenylketonuria, and their families. The program aims to help in diagnosis and assist the people for treatment of phenylketonuria. Furthermore, launches of novel products by U.S.-based key players is also expected to drive growth of North America phenylketonuria treatment market. For instance, in 2017, Vitaflo USA, LLC launched its new PKU Sphere, a low phenylalanine medical food used in dietary management of Phenylketonuria (PKU). Europe is also expected to exhibit significant growth in the near future, owing to increasing approval of new drugs in the region. For instance in 2015, Merck Group, a Germany-based company, received EU-approval to extend the use of Kuvan in children below four years of age suffering from Phenylketonuria.

Phenylketonuria Treatment Market Restraint

According to data published by The ZB Foundation in 2017, Phenylketonuria is a rare inherited disease that affects only about 1 in 10,000 to 15,000 newborn children. The lack of awareness about the rare disease is a major factor, which is expected to restrain growth of the market in the near future.

Phenylketonuria Treatment Market Key Players

Key players operating in global phenylketonuria treatment market include BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., American Gene Technologies International Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA. Key Players in global phenylketonuria treatment market are focusing on strategic collaborations for the development of novel therapies for the treatment of phenylketonuria. For instance, in January 2018, Retrophin, Inc. and Censa Pharmaceuticals collaborated for the development and evaluation of CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001, is an orally bioavailable proprietary form of sepiapterin, serves as a natural precursor of tetrahydrobiopterin (BH4) that is converted by an endogenous enzymatic pathway to BH4.

Get PDF Brochure of This Business Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1648

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Phenylketonuria Treatment Market Challenges with Top Players BioMarin Pharmaceutical,Dimension Therapeutics, American Gene, Synthetic Biologics here

News-ID: 1798182 • Views:

More Releases from Coherent Market Insights

Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abbott Laboratories, Amway, Atkins, Blue Diamond Growers
Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abb …
The Meal Replacement Market is estimated to be valued at USD 14.82 Bn in 2025 and is expected to reach USD 22.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Meal Replacement Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion by 2032 with a 7.9% CAGR |C&D Technologies Inc., Crown Battery Manufacturing Co., East Penn Manufacturing Co. Inc., EnerSys
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion …
The deep cycle battery market is estimated to be valued at USD 2.77 billion in 2025 and is expected to reach USD 4.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Deep Cycle Battery Market, Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by 2025-2032 |Hangzhou Xunda Packaging Co., Smurfit Kappa Group PLC, DS Smith Plc, Pregis Corporation
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by …
The consumer electronics packaging market is estimated to be valued at USD 26.57 Bn in 2025 and is expected to reach USD 81.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Consumer Electronics Packaging Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koninklijke DSM N.V., BAE Systems, Morgan Advanced Materials , Saint-Gobain S.A.
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koni …
The global ceramic armor market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 4.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Ceramic Armor Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,

All 5 Releases


More Releases for Phenylketonuria

Global Phenylketonuria (PKU) Market Status and Outlook (2015-2025)
Market Overview The Phenylketonuria (PKU) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. The global Phenylketonuria (PKU) market size is expected to gain market growth in the forecast period of 2020 to
Phenylketonuria (PKU) Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Phenylketonuria (PKU) market analysis, which studies the Phenylketonuria (PKU)'s industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “Phenylketonuria (PKU) Market 2020-2025” Research Report categorizes the global Phenylketonuria (PKU) market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
Phenylketonuria Treatment Market Size, Share, Trends, Analysis and Forecast - 20 …
The phenylketonuria (PKU) treatment market is anticipated to grow at a lucrative growth during the forecast period. PKU is a genetic metabolism defect that results in decreased metabolism of the amino acid called phenylalanine. PKU has no definite cure yet, it can only be managed using additional therapy and diet controls. Unmanaged PKU can lead to various intellectual disability, seizures, behavioral and mental disorders in children. In 2019, the global
Phenylketonuria Treatment Market : Factors Helping to Maintain Strong Position G …
Zion Market Research analysts forecast the latest report on "Global Phenylketonuria Treatment Market Set for Rapid Growth, to reach Value around USD 925.0 Million by 2025", according to their latest report the Phenylketonuria Treatment Market report covers the overall and all-inclusive analysis of the Phenylketonuria Treatment Market with all its factors that have an impact on market growth. The Phenylketonuria Treatment Market's complete outline is crystal clear penned down in
Phenylketonuria Market development trends, key manufacturers and competitive ana …
Phenylketonuria Market research report is a meticulous investigation of current scenario of the market, which covers several market dynamics. The Market Report also provides an analytical assessment of the prime challenges faced by Phenylketonuria Market currently and in the coming years, which helps Market participants in understanding the problems they may face while operating in this Market over a longer period of time. Phenylketonuria (PKU) is an inborn error of metabolism
Global Phenylketonuria Market Drivers and Challenges Report 2017
“Global Phenylketonuria Market Professional Survey Report 2017” Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. This report studies the Phenylketonuria (PKU) market. Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly